Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
Gursimran S KochharAakash DesaiFrancis A FarrayeRaymond K CrossSandra El-HachemParambir S DulaiMiguel RegueiroPublished in: Alimentary pharmacology & therapeutics (2023)
Ustekinumab might be the preferred second-line therapy over tofacitinib and vedolizumab in patients with UC that were previously exposed to a TNFi.